Retatrutide fatty liver protocol estimator
Estimate liver fat reduction outcomes with retatrutide based on your fibrosis stage and current liver fat percentage. Based on the Phase 2 NAFLD sub-study showing 86% liver fat clearance.
Phase 2 trial finding
In a dedicated NAFLD sub-study, retatrutide cleared 86% of liver fat and returned 93% of patients to normal liver fat levels. No approved drug comes close to this outcome. 1 in 3 adults have fatty liver disease.
Liver fat reduction
86%
Patients normalized
93%
Projected residual fat
2.8–2.8%
Expected timeframe
24–36 weeks
Best outcomes at F0. Phase 2 data showed near-complete liver fat clearance at this stage. 93% of patients reached normal liver fat levels.
Recommended protocol
| Weeks | Dose | Phase note |
|---|---|---|
| 1–4 | 1 mg | Initiation — GI tolerance phase |
| 5–8 | 2 mg | Early escalation |
| 9–12 | 4 mg | Therapeutic range begins |
| 13–16 | 8 mg | Liver fat reduction accelerates |
| 17+ | 12 mg | Maintenance — maximum efficacy |
Research use only. This calculator is provided for educational and research purposes only. It does not constitute medical advice. Consult a licensed physician before use.
References
Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972